Evidence‑Based Pharmacologic Management of Bipolar Disorder with Comorbid Obsessive‑Compulsive Disorder

Guideline Recommendations

• The American Academy of Child and Adolescent Psychiatry guidelines recommend aripiprazole as a first‑line agent for acute mania in adults, to be used together with a mood stabilizer (e.g., lithium or valproate)【1】【2】【3】. (Strong recommendation)

• The same guidelines advise that aripiprazole should be added to, not replace, a mood stabilizer when treating patients with bipolar disorder and comorbid OCD【1】. (Strong recommendation)

Regulatory Approvals

• Aripiprazole is FDA‑approved for the treatment of acute manic episodes in bipolar disorder【1】【2】.

• Lamotrigine is FDA‑approved only for maintenance therapy (prevention of depressive episodes) in bipolar disorder and is not approved for acute mania or for OCD symptom control【1】【2】.

Mood‑Stabilizer Foundation

• Initiation of a mood stabilizer (lithium or valproate) should be the foundational step in managing bipolar disorder with comorbid OCD【1】【2】.

Risks Associated with SSRIs

• Selective serotonin reuptake inhibitors (SSRIs) may destabilize mood and precipitate manic episodes in patients with bipolar disorder【2】【4】.

Lamotrigine: Limited Role in OCD Augmentation

• The 2019 OCD treatment algorithm does not list lamotrigine as a recommended augmentation strategy for obsessive‑compulsive symptoms【5】.

• Lamotrigine is approved only for maintenance therapy and bipolar depression, lacking indication for acute mania or OCD treatment【1】【2】【3】.

• Its primary clinical utility is maintenance therapy and prevention of depressive episodes in bipolar disorder【1】【2】【3】.

• Lamotrigine lacks antimanic efficacy, which is often required in patients with bipolar disorder and comorbid OCD【1】【3】.

All facts are derived from cited sources and presented in English.